

**ANZ
DATA**



AUSTRALIA &
NEW ZEALAND

DIALYSIS & TRANSPLANT
REGISTRY

MISSING DATA REPORT

Survey Data 2020 – 2024

[Abstract](#)

The rates of non-response for ANZDATA
survey items over the last 5 years

anzdata@anzdata.org.au

www.anzorgg.org.au

ANZDATA Missing Data Report



The tables below show the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

Table 1 Demographics

Variable	2020	2021	2022	2023	2024
Frequency	4064	4103	4188	4245	4250
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	13 (0.3%)	41 (1.0%)	15 (0.4%)	19 (0.4%)	30 (0.7%)
Late referral seen <3 mths before 1st treatment	38 (0.9%)	63 (1.5%)	43 (1.0%)	92 (2.2%)	15 (0.4%)
Ethnicity 1	76 (1.9%)	57 (1.4%)	73 (1.7%)	91 (2.1%)	103 (2.4%)
Primary kidney disease major heading	25 (0.6%)	19 (0.5%)	35 (0.8%)	54 (1.3%)	23 (0.5%)
Was native kidney biopsied?	50 (1.2%)	69 (1.7%)	46 (1.1%)	93 (2.2%)	110 (2.6%)
Genetic test performed?	2615 (64.3%)	2438 (59.4%)	2270 (54.2%)	414 (9.8%)	175 (4.1%)
Serum creatinine at entry	67 (1.6%)	51 (1.2%)	42 (1.0%)	41 (1.0%)	21 (0.5%)
Height at KRT entry (cm)	75 (1.8%)	70 (1.7%)	66 (1.6%)	72 (1.7%)	49 (1.2%)
Weight at KRT entry (kg)	29 (0.7%)	56 (1.4%)	33 (0.8%)	37 (0.9%)	22 (0.5%)
Smoking status at KRT entry	53 (1.3%)	84 (2.0%)	65 (1.6%)	65 (1.5%)	60 (1.4%)

Table 2 Comorbidities at KRT entry

Variable	2020	2021	2022	2023	2024
Frequency	4064	4103	4188	4245	4250
Postcode	30 (0.7%)	46 (1.1%)	35 (0.8%)	31 (0.7%)	35 (0.8%)
Chronic lung disease	31 (0.8%)	18 (0.4%)	28 (0.7%)	77 (1.8%)	69 (1.6%)
Coronary artery disease	32 (0.8%)	18 (0.4%)	29 (0.7%)	79 (1.9%)	74 (1.7%)
Peripheral vascular disease	30 (0.7%)	17 (0.4%)	30 (0.7%)	80 (1.9%)	71 (1.7%)
Cerebrovascular disease	31 (0.8%)	19 (0.5%)	31 (0.7%)	75 (1.8%)	71 (1.7%)
Diabetes	30 (0.7%)	41 (1.0%)	31 (0.7%)	77 (1.8%)	69 (1.6%)
Cancer ever diagnosed?	22 (0.5%)	111 (2.7%)	37 (0.9%)	87 (2.0%)	86 (2.0%)
Hepatitis C Antibody	48 (1.2%)	25 (0.6%)	38 (0.9%)	89 (2.1%)	94 (2.2%)
Calciphylaxis Episode	31 (0.8%)	57 (1.4%)	21 (0.5%)	91 (2.1%)	89 (2.1%)
Non-Registry Trials	155 (3.8%)	869 (21.2%)	186 (4.4%)	978 (23.0%)	962 (22.6%)

ANZDATA Missing Data Report



Table 3 Comorbidities at survey date

Variable	2020	2021	2022	2023	2024
Frequency	36879	38136	39325	39828	40685
Postcode	153 (0.4%)	441 (1.2%)	423 (1.1%)	395 (1.0%)	442 (1.1%)
Chronic lung disease	167 (0.5%)	163 (0.4%)	144 (0.4%)	194 (0.5%)	217 (0.5%)
Coronary artery disease	167 (0.5%)	163 (0.4%)	145 (0.4%)	196 (0.5%)	222 (0.5%)
Peripheral vascular disease	166 (0.5%)	161 (0.4%)	149 (0.4%)	198 (0.5%)	222 (0.5%)
Cerebrovascular disease	170 (0.5%)	167 (0.4%)	149 (0.4%)	195 (0.5%)	222 (0.5%)
Diabetes	159 (0.4%)	181 (0.5%)	141 (0.4%)	190 (0.5%)	212 (0.5%)
Cancer ever diagnosed?	129 (0.3%)	223 (0.6%)	123 (0.3%)	168 (0.4%)	206 (0.5%)
Hepatitis C Antibody	215 (0.6%)	152 (0.4%)	156 (0.4%)	223 (0.6%)	238 (0.6%)
Calciphylaxis Episode	882 (2.4%)	912 (2.4%)	120 (0.3%)	198 (0.5%)	659 (1.6%)
Non-Registry Trials	1189 (3.2%)	3098 (8.1%)	505 (1.3%)	2764 (6.9%)	23856 (58.6%)

Table 4 Reason for change from CAPD to APD

Variable	2020	2021	2022	2023	2024
Frequency	635	643	670	589	599
Reason transfer from dialysis during survey	54 (8.5%)	131 (20.4%)	72 (10.7%)	24 (4.1%)	8 (1.3%)

Table 5 Reason for change from APD to CAPD

Variable	2020	2021	2022	2023	2024
Frequency	112	169	105	111	141
Reason transfer from dialysis during survey	16 (14.3%)	65 (38.5%)	11 (10.5%)	0 (0.0%)	3 (2.1%)

Table 6 Reason for change from PD to HD

Variable	2020	2021	2022	2023	2024
Frequency	840	919	846	873	883
Reason transfer from dialysis during survey	52 (6.2%)	82 (8.9%)	51 (6.0%)	16 (1.8%)	26 (2.9%)

Table 7 Reason for change from HD to PD

Variable	2020	2021	2022	2023	2024
Frequency	522	509	476	530	450
Reason transfer from dialysis during survey	31 (5.9%)	56 (11.0%)	24 (5.0%)	8 (1.5%)	4 (0.9%)

Table 8 Reason for change from Hybrid to PD

Variable	2020	2021	2022	2023	2024
Frequency	0	0	0	0	5
Reason transfer from dialysis during survey	-	-	-	-	0 (0.0%)

ANZDATA Missing Data Report



Table 9 Reason for change from PD to Hybrid

Variable	2020	2021	2022	2023	2024
Frequency	0	0	0	24	50
Reason transfer from dialysis during survey	-	-	-	1 (4.2%)	1 (2.0%)

Table 10 Cause of death

Variable	2020	2021	2022	2023	2024
Frequency	2847	2999	3742	3393	3230
Cause of death	111 (3.9%)	103 (3.4%)	175 (4.7%)	90 (2.7%)	59 (1.8%)

Table 11 Dialysis data

Variable	2020	2021	2022	2023	2024
Frequency	21119	21925	22780	23089	23402
Dialysis type	1050 (5.0%)	1204 (5.5%)	863 (3.8%)	793 (3.4%)	759 (3.2%)
Self-care dialysis (performed by the patient with minimal assistance)	1260 (6.0%)	1225 (5.6%)	885 (3.9%)	803 (3.5%)	1285 (5.5%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	1176 (5.6%)	1526 (7.0%)	1029 (4.5%)	929 (4.0%)	877 (3.7%)
Uncorrected calcium levels (mmol/l)	1453 (6.9%)	1389 (6.3%)	1427 (6.3%)	1050 (4.5%)	983 (4.2%)
Phosphate levels (mmol/l)	1427 (6.8%)	1404 (6.4%)	1428 (6.3%)	1049 (4.5%)	985 (4.2%)
Haemoglobin level nearest end Survey (g/l)	1413 (6.7%)	1373 (6.3%)	1412 (6.2%)	1024 (4.4%)	974 (4.2%)
EPO Agent	1259 (6.0%)	1716 (7.8%)	1444 (6.3%)	967 (4.2%)	837 (3.6%)
Ferritin within last 3 months of Survey	2604 (12.3%)	2582 (11.8%)	2776 (12.2%)	2410 (10.4%)	2474 (10.6%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	2961 (14.0%)	2819 (12.9%)	3068 (13.5%)	2687 (11.6%)	2652 (11.3%)

Table 12 Haemodialysis data

Variable	2020	2021	2022	2023	2024
Frequency	17416	18138	18914	19269	19578
Dialyser brand, model, membrane, surface area	901 (5.2%)	1015 (5.6%)	865 (4.6%)	779 (4.0%)	734 (3.7%)
Blood flow rate (mls/min)	912 (5.2%)	1029 (5.7%)	880 (4.7%)	764 (4.0%)	733 (3.7%)
Frequency of dialysis per week	884 (5.1%)	1010 (5.6%)	865 (4.6%)	740 (3.8%)	727 (3.7%)
Hours per session	899 (5.2%)	1046 (5.8%)	856 (4.5%)	744 (3.9%)	729 (3.7%)
Adequacy method (urea reduction or Kt/V)	3186 (18.3%)	3567 (19.7%)	3606 (19.1%)	3200 (16.6%)	3170 (16.2%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	3186 (18.3%)	3567 (19.7%)	3606 (19.1%)	3224 (16.7%)	3185 (16.3%)
Vascular access in use at last haemodialysis	935 (5.4%)	1093 (6.0%)	875 (4.6%)	797 (4.1%)	770 (3.9%)

Table 13 HDF volume

Variable	2020	2021	2022	2023	2024
Frequency	5240	4979	5196	5379	5610
HDF volume (L) (If on HDF)	653 (12.5%)	472 (9.5%)	728 (14.0%)	559 (10.4%)	352 (6.3%)

ANZDATA Missing Data Report



Table 14 Access at first HD

Variable	2020	2021	2022	2023	2024
Frequency	3314	3461	3596	3623	3647
Vascular access in use at first haemodialysis	126 (3.8%)	105 (3.0%)	102 (2.8%)	70 (1.9%)	38 (1.0%)

Table 15 Peritoneal dialysis data

Variable	2020	2021	2022	2023	2024
Frequency	4866	4963	4989	5006	4970
Type of Peritoneal Connection System	310 (6.4%)	366 (7.4%)	203 (4.1%)	174 (3.5%)	186 (3.7%)
Total volume weekly exchanges - All PD	337 (6.9%)	646 (13.0%)	258 (5.2%)	215 (4.3%)	240 (4.8%)
PD Solution Glucose	325 (6.7%)	420 (8.5%)	225 (4.5%)	180 (3.6%)	207 (4.2%)
PD Solution Icodextrin	326 (6.7%)	421 (8.5%)	227 (4.6%)	179 (3.6%)	209 (4.2%)
PD Solution Low GDP (either Lactate or Bicarbonate)	331 (6.8%)	424 (8.5%)	231 (4.6%)	184 (3.7%)	212 (4.3%)
Creatinine Clearance (litres/week/1.73m ²)	1982 (40.7%)	2175 (43.8%)	2025 (40.6%)	2224 (44.4%)	1945 (39.1%)
Dialysate Only Weekly Kt/V value on PD	1979 (40.7%)	2156 (43.4%)	2015 (40.4%)	2226 (44.5%)	1939 (39.0%)
Residual kidney function (creatinine clearance - litres/week/1.73m ²)	1989 (40.9%)	2191 (44.1%)	2042 (40.9%)	2239 (44.7%)	1966 (39.6%)
Number of episodes peritonitis during survey	949 (19.5%)	1208 (24.3%)	1077 (21.6%)	1440 (28.8%)	1920 (38.6%)
Residual Urine Volume (mL/24 hrs)	2863 (58.8%)	2655 (53.5%)	2466 (49.4%)	2537 (50.7%)	2095 (42.2%)

Table 16 Peritoneal dialysis PET test

Variable	2020	2021	2022	2023	2024
Frequency	1544	1488	1398	1488	1404
PET test for PD-within first 6 mths starting?	1011 (65.5%)	1002 (67.3%)	935 (66.9%)	884 (59.4%)	870 (62.0%)

Table 17 Peritoneal dialysis catheter date

Variable	2020	2021	2022	2023	2024
Frequency	0	0	0	1488	1404
First peritoneal catheter insertion date	-	-	-	35 (2.4%)	8 (0.6%)

Table 18 Peritonitis episodes data

Variable	2020	2021	2022	2023	2024
Frequency	989	1048	1217	1250	1156
Was this a relapse or recurrence of peritonitis?	8 (0.8%)	7 (0.7%)	6 (0.5%)	4 (0.3%)	6 (0.5%)
Technique at time of infection	3 (0.3%)	2 (0.2%)	1 (0.1%)	2 (0.2%)	0 (0.0%)
Antifungal Therapy?	48 (4.9%)	33 (3.1%)	11 (0.9%)	10 (0.8%)	9 (0.8%)
Name of initial regimen first antibiotic given	21 (2.1%)	7 (0.7%)	3 (0.2%)	3 (0.2%)	7 (0.6%)
Name of final regimen first antibiotic given	49 (5.0%)	18 (1.7%)	25 (2.1%)	8 (0.6%)	70 (6.1%)
Glucose PD Solution at time of infection?	53 (5.4%)	53 (5.1%)	35 (2.9%)	27 (2.2%)	31 (2.7%)
Icodextrin PD Solution at time of infection?	58 (5.9%)	53 (5.1%)	36 (3.0%)	27 (2.2%)	32 (2.8%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	62 (6.3%)	55 (5.2%)	40 (3.3%)	30 (2.4%)	34 (2.9%)
Was patient hospitalised overnight?	41 (4.1%)	5 (0.5%)	6 (0.5%)	6 (0.5%)	7 (0.6%)

ANZDATA Missing Data Report



Was catheter removed?	36 (3.6%)	9 (0.9%)	7 (0.6%)	15 (1.2%)	11 (1.0%)
Did patient have interim haemodialysis?	38 (3.8%)	11 (1.0%)	16 (1.3%)	23 (1.8%)	12 (1.0%)
Did patient transfer to permanent haemodialysis?	40 (4.0%)	11 (1.0%)	10 (0.8%)	16 (1.3%)	13 (1.1%)

Table 19 Transplant baseline data

Variable	2020	2021	2022	2023	2024
Frequency	1072	1044	1112	1264	1262
Recipient CMV antibody status	54 (5.0%)	25 (2.4%)	4 (0.4%)	41 (3.2%)	11 (0.9%)
Recipient EBV antibody status	55 (5.1%)	25 (2.4%)	3 (0.3%)	40 (3.2%)	12 (1.0%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	35 (3.3%)	21 (2.0%)	21 (1.9%)	56 (4.4%)	27 (2.1%)
Immediate function	18 (1.7%)	12 (1.1%)	10 (0.9%)	52 (4.1%)	17 (1.3%)
HLA-A mismatch	9 (0.8%)	0 (0.0%)	2 (0.2%)	9 (0.7%)	0 (0.0%)
HLA-B mismatch	9 (0.8%)	0 (0.0%)	2 (0.2%)	9 (0.7%)	0 (0.0%)
HLA-DR mismatch	9 (0.8%)	0 (0.0%)	2 (0.2%)	9 (0.7%)	0 (0.0%)
HLA-DQ mismatch	85 (7.9%)	12 (1.1%)	2 (0.2%)	9 (0.7%)	0 (0.0%)
Donor blood group	4 (0.4%)	0 (0.0%)	0 (0.0%)	1 (0.1%)	0 (0.0%)
Recipient blood group	3 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.1%)	0 (0.0%)
Recipient authorised match PRA from OrganMatch	9 (0.8%)	0 (0.0%)	2 (0.2%)	9 (0.7%)	0 (0.0%)

Table 20 Transplant Surgical data - of all transplants

Variable	2020	2021	2022	2023	2024
Frequency	1072	1044	1112	1264	1262
At least one anastomosis in transplant surgical data	245 (22.9%)	98 (9.4%)	39 (3.5%)	88 (7.0%)	80 (6.3%)

Table 21 Transplant Surgical data - of all anastomoses

Variable	2020	2021	2022	2023	2024
Frequency	872	977	1093	1187	1208
Anastomosis site	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Arterial	26 (3.0%)	28 (2.9%)	2 (0.2%)	7 (0.6%)	7 (0.6%)
Venous	29 (3.3%)	28 (2.9%)	3 (0.3%)	7 (0.6%)	7 (0.6%)
Vena cava extension	28 (3.2%)	8 (0.8%)	3 (0.3%)	12 (1.0%)	29 (2.4%)
Aortic patch	25 (2.9%)	6 (0.6%)	2 (0.2%)	11 (0.9%)	26 (2.2%)
Anastomosis time (min)	51 (5.8%)	30 (3.1%)	26 (2.4%)	25 (2.1%)	16 (1.3%)

ANZDATA Missing Data Report



Table 22 Graft failure data

Variable	2020	2021	2022	2023	2024
Frequency	324	342	384	354	334
Cause of graft failure	19 (5.9%)	12 (3.5%)	17 (4.4%)	15 (4.2%)	17 (5.1%)
Serum creatinine at graft failure	35 (10.8%)	25 (7.3%)	51 (13.3%)	33 (9.3%)	31 (9.3%)

Table 23 Rejection data

Variable	2020	2021	2022	2023	2024
Frequency	415	363	314	487	425
Was a biopsy performed?	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Response of this rejection to treatment	44 (10.6%)	40 (11.0%)	24 (7.6%)	23 (4.7%)	11 (2.6%)
Primary treatment of rejection	20 (4.8%)	10 (2.8%)	3 (1.0%)	14 (2.9%)	2 (0.5%)

Table 24 Rejection data if biopsy performed

Variable	2020	2021	2022	2023	2024
Frequency	410	350	306	475	418
If biopsy is Yes ?Cellular	336 (82.0%)	-	-	-	-
If biopsy is Yes ?Glomerular	335 (81.7%)	-	-	-	-
If biopsy is Yes ?Vascular	335 (81.7%)	-	-	-	-
Humoral Rejection	335 (81.7%)	-	-	-	-
If biopsy is Yes ?Antibody mediated	162 (39.5%)	6 (1.7%)	3 (1.0%)	7 (1.5%)	0 (0.0%)
If biopsy is Yes ?T-cell mediated	154 (37.6%)	7 (2.0%)	4 (1.3%)	8 (1.7%)	4 (1.0%)
If biopsy is Yes ?Presence of donor specific antibody(DSA)	337 (82.2%)	233 (66.6%)	199 (65.0%)	287 (60.4%)	251 (60.0%)
If biopsy is Yes and Banff g is known	44 (10.7%)	34 (9.7%)	37 (12.1%)	71 (14.9%)	39 (9.3%)
If biopsy is Yes and Banff i is known	41 (10.0%)	37 (10.6%)	30 (9.8%)	65 (13.7%)	35 (8.4%)
If biopsy is Yes and Banff t is known	37 (9.0%)	33 (9.4%)	30 (9.8%)	48 (10.1%)	28 (6.7%)
If biopsy is Yes and Banff v is known	48 (11.7%)	57 (16.3%)	50 (16.3%)	86 (18.1%)	52 (12.4%)
If biopsy is Yes and Banff ptc is known	51 (12.4%)	48 (13.7%)	52 (17.0%)	76 (16.0%)	46 (11.0%)
If biopsy is Yes and Banff c4d is known	202 (49.3%)	84 (24.0%)	76 (24.8%)	116 (24.4%)	72 (17.2%)
If biopsy is Yes and Banff cg is known	208 (50.7%)	73 (20.9%)	58 (19.0%)	115 (24.2%)	70 (16.7%)
If biopsy is Yes and Banff ci is known	220 (53.7%)	69 (19.7%)	59 (19.3%)	86 (18.1%)	62 (14.8%)
If biopsy is Yes and Banff ct is known	219 (53.4%)	69 (19.7%)	58 (19.0%)	90 (18.9%)	64 (15.3%)
If biopsy is Yes and Banff cv is known	220 (53.7%)	80 (22.9%)	69 (22.5%)	118 (24.8%)	80 (19.1%)
If biopsy is Yes and Banff mm is known	239 (58.3%)	132 (37.7%)	93 (30.4%)	142 (29.9%)	136 (32.5%)
If biopsy is Yes and Banff ah is known	205 (50.0%)	80 (22.9%)	83 (27.1%)	121 (25.5%)	103 (24.6%)
If biopsy is Yes and Banff ti is known	237 (57.8%)	116 (33.1%)	88 (28.8%)	130 (27.4%)	95 (22.7%)
If biopsy is Yes and Banff i-IFTA is known	253 (61.7%)	140 (40.0%)	103 (33.7%)	174 (36.6%)	126 (30.1%)

ANZDATA Missing Data Report



Table 25 Rejection data if biopsy not performed

Variable	2020	2021	2022	2023	2024
Frequency	5	13	8	12	7
Likelihood of rejection if biopsy not performed	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 26 Transplant follow-up data, 0 months

Variable	2020	2021	2022	2023	2024
Frequency	1079	1057	1134	1290	1277
Weight	59 (5.5%)	32 (3.0%)	87 (7.7%)	61 (4.7%)	31 (2.4%)
Drug data	25 (2.3%)	33 (3.1%)	89 (7.8%)	64 (5.0%)	29 (2.3%)

Table 27 Transplant follow-up data, 1 months

Variable	2020	2021	2022	2023	2024
Frequency	1057	1027	1109	1271	1275
Weight	50 (4.7%)	66 (6.4%)	67 (6.0%)	67 (5.3%)	60 (4.7%)
Serum creatinine	30 (2.8%)	60 (5.8%)	57 (5.1%)	60 (4.7%)	49 (3.8%)
Drug data	31 (2.9%)	72 (7.0%)	97 (8.7%)	67 (5.3%)	47 (3.7%)

Table 28 Transplant follow-up data, 2 months

Variable	2020	2021	2022	2023	2024
Frequency	1054	1053	1063	1252	1320
Weight	79 (7.5%)	109 (10.4%)	113 (10.6%)	128 (10.2%)	106 (8.0%)
Serum creatinine	50 (4.7%)	84 (8.0%)	92 (8.7%)	102 (8.1%)	83 (6.3%)
Drug data	54 (5.1%)	102 (9.7%)	119 (11.2%)	103 (8.2%)	79 (6.0%)

Table 29 Transplant follow-up data, 3 months

Variable	2020	2021	2022	2023	2024
Frequency	1089	1052	1068	1226	1296
Weight	89 (8.2%)	125 (11.9%)	126 (11.8%)	137 (11.2%)	108 (8.3%)
Serum creatinine	64 (5.9%)	103 (9.8%)	100 (9.4%)	104 (8.5%)	85 (6.6%)
Drug data	70 (6.4%)	109 (10.4%)	128 (12.0%)	102 (8.3%)	81 (6.2%)

Table 30 Transplant follow-up data, 6 months

Variable	2020	2021	2022	2023	2024
Frequency	1073	1114	1032	1188	1252
Weight	155 (14.4%)	180 (16.2%)	154 (14.9%)	203 (17.1%)	188 (15.0%)
Serum creatinine	111 (10.3%)	128 (11.5%)	113 (10.9%)	147 (12.4%)	144 (11.5%)
Drug data	117 (10.9%)	142 (12.7%)	135 (13.1%)	157 (13.2%)	140 (11.2%)

Table 31 Transplant follow-up data, 12 months

Variable	2020	2021	2022	2023	2024
----------	------	------	------	------	------

ANZDATA Missing Data Report



Frequency	1281	1030	1004	1090	1241
Weight	193 (15.1%)	161 (15.6%)	184 (18.3%)	169 (15.5%)	218 (17.6%)
Serum creatinine	146 (11.4%)	110 (10.7%)	128 (12.7%)	123 (11.3%)	154 (12.4%)
Drug data	135 (10.5%)	120 (11.7%)	148 (14.7%)	119 (10.9%)	155 (12.5%)

Table 32 Transplant follow-up data, 24 months

Variable	2020	2021	2022	2023	2024
Frequency	1268	1251	995	970	1066
Weight	212 (16.7%)	185 (14.8%)	178 (17.9%)	167 (17.2%)	178 (16.7%)
Serum creatinine	133 (10.5%)	122 (9.8%)	121 (12.2%)	123 (12.7%)	115 (10.8%)
Drug data	139 (11.0%)	137 (11.0%)	141 (14.2%)	125 (12.9%)	117 (11.0%)

Table 33 Transplant follow-up data, 36 months

Variable	2020	2021	2022	2023	2024
Frequency	1199	1239	1202	959	947
Weight	215 (17.9%)	207 (16.7%)	185 (15.4%)	158 (16.5%)	155 (16.4%)
Serum creatinine	148 (12.3%)	105 (8.5%)	121 (10.1%)	106 (11.1%)	110 (11.6%)
Drug data	150 (12.5%)	114 (9.2%)	136 (11.3%)	106 (11.1%)	115 (12.1%)

Table 34 Transplant follow-up data, 60 months

Variable	2020	2021	2022	2023	2024
Frequency	917	1093	1099	1147	1109
Weight	172 (18.8%)	199 (18.2%)	181 (16.5%)	192 (16.7%)	177 (16.0%)
Serum creatinine	103 (11.2%)	118 (10.8%)	116 (10.6%)	120 (10.5%)	113 (10.2%)
Drug data	108 (11.8%)	127 (11.6%)	118 (10.7%)	130 (11.3%)	122 (11.0%)

Table 35 Transplant follow-up data, 84 months

Variable	2020	2021	2022	2023	2024
Frequency	786	824	830	1013	996
Weight	150 (19.1%)	156 (18.9%)	124 (14.9%)	182 (18.0%)	197 (19.8%)
Serum creatinine	97 (12.3%)	93 (11.3%)	72 (8.7%)	125 (12.3%)	134 (13.5%)
Drug data	97 (12.3%)	100 (12.1%)	75 (9.0%)	134 (13.2%)	140 (14.1%)

Table 36 Transplant follow-up data, 120 months

Variable	2020	2021	2022	2023	2024
Frequency	646	626	636	669	685
Weight	124 (19.2%)	117 (18.7%)	117 (18.4%)	125 (18.7%)	150 (21.9%)
Serum creatinine	83 (12.8%)	72 (11.5%)	70 (11.0%)	79 (11.8%)	97 (14.2%)
Drug data	90 (13.9%)	77 (12.3%)	73 (11.5%)	82 (12.3%)	100 (14.6%)

Table 37 Transplant follow-up data, 180 months

ANZDATA Missing Data Report



Variable	2020	2021	2022	2023	2024
Frequency	343	356	345	439	473
Weight	57 (16.6%)	66 (18.5%)	62 (18.0%)	80 (18.2%)	84 (17.8%)
Serum creatinine	32 (9.3%)	34 (9.6%)	40 (11.6%)	56 (12.8%)	59 (12.5%)
Drug data	39 (11.4%)	40 (11.2%)	42 (12.2%)	59 (13.4%)	63 (13.3%)

Table 38 Transplant follow-up data, 240 months

Variable	2020	2021	2022	2023	2024
Frequency	219	215	259	222	271
Weight	48 (21.9%)	42 (19.5%)	49 (18.9%)	53 (23.9%)	47 (17.3%)
Serum creatinine	31 (14.2%)	30 (14.0%)	27 (10.4%)	37 (16.7%)	30 (11.1%)
Drug data	34 (15.5%)	30 (14.0%)	28 (10.8%)	39 (17.6%)	30 (11.1%)

Table 39 Transplant follow-up data, 300 months

Variable	2020	2021	2022	2023	2024
Frequency	105	131	142	140	128
Weight	21 (20.0%)	31 (23.7%)	33 (23.2%)	37 (26.4%)	28 (21.9%)
Serum creatinine	16 (15.2%)	14 (10.7%)	29 (20.4%)	23 (16.4%)	19 (14.8%)
Drug data	17 (16.2%)	15 (11.5%)	29 (20.4%)	24 (17.1%)	19 (14.8%)

Table 40 Transplant follow-up data, 360 months

Variable	2020	2021	2022	2023	2024
Frequency	50	56	67	49	64
Weight	10 (20.0%)	15 (26.8%)	15 (22.4%)	12 (24.5%)	11 (17.2%)
Serum creatinine	7 (14.0%)	8 (14.3%)	8 (11.9%)	9 (18.4%)	7 (10.9%)
Drug data	6 (12.0%)	8 (14.3%)	9 (13.4%)	8 (16.3%)	8 (12.5%)

Table 41 Transplant follow-up data, 420 months

Variable	2020	2021	2022	2023	2024
Frequency	29	32	30	30	32
Weight	8 (27.6%)	6 (18.8%)	5 (16.7%)	3 (10.0%)	4 (12.5%)
Serum creatinine	5 (17.2%)	1 (3.1%)	4 (13.3%)	1 (3.3%)	1 (3.1%)
Drug data	5 (17.2%)	2 (6.2%)	4 (13.3%)	1 (3.3%)	2 (6.2%)

Table 42 Transplant follow-up data, 480 months

Variable	2020	2021	2022	2023	2024
Frequency	14	18	15	15	14
Weight	4 (28.6%)	5 (27.8%)	3 (20.0%)	5 (33.3%)	4 (28.6%)
Serum creatinine	3 (21.4%)	2 (11.1%)	2 (13.3%)	3 (20.0%)	3 (21.4%)
Drug data	3 (21.4%)	2 (11.1%)	2 (13.3%)	3 (20.0%)	3 (21.4%)

ANZDATA Missing Data Report



Table 43 Transplant follow-up data, 540 months

Variable	2020	2021	2022	2023	2024
Frequency	4	7	10	9	10
Weight	0 (0.0%)	1 (14.3%)	0 (0.0%)	4 (44.4%)	6 (60.0%)
Serum creatinine	0 (0.0%)	1 (14.3%)	0 (0.0%)	1 (11.1%)	4 (40.0%)
Drug data	0 (0.0%)	1 (14.3%)	0 (0.0%)	1 (11.1%)	5 (50.0%)

Table 44 Transplant follow-up data, 600 months

Variable	2020	2021	2022	2023	2024
Frequency	0	0	0	0	0
Weight	-	-	-	-	-
Serum creatinine	-	-	-	-	-
Drug data	-	-	-	-	-

Table 45 Paediatric assessment at entry

Variable	2020	2021	2022	2023	2024
Frequency	31	34	44	31	35
Height	1 (3.2%)	0 (0.0%)	1 (2.3%)	3 (9.7%)	0 (0.0%)
Weight	0 (0.0%)	0 (0.0%)	1 (2.3%)	3 (9.7%)	0 (0.0%)
Paediatric Assessment at end of each Survey	1 (3.2%)	3 (8.8%)	2 (4.5%)	4 (12.9%)	0 (0.0%)

Table 46 Paediatric assessment at entry - mainstream school

Variable	2020	2021	2022	2023	2024
Frequency	18	18	22	11	17
Attendance limited by dialysis? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Attendance limited by renal health? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Supervised education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Additional education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 47 Paediatric assessment at survey

Variable	2020	2021	2022	2023	2024
Frequency	356	360	366	364	356
Height	33 (9.3%)	9 (2.5%)	7 (1.9%)	32 (8.8%)	7 (2.0%)
Weight	32 (9.0%)	5 (1.4%)	2 (0.5%)	31 (8.5%)	7 (2.0%)
Paediatric Assessment at end of each Survey	27 (7.6%)	5 (1.4%)	3 (0.8%)	31 (8.5%)	7 (2.0%)

ANZDATA Missing Data Report



Table 48 Paediatric assessment at survey - mainstream school

Variable	2020	2021	2022	2023	2024
Frequency	245	267	263	237	246
Attendance limited by dialysis? (If in mainstream school)	2 (0.8%)	2 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Attendance limited by renal health? (If in mainstream school)	2 (0.8%)	2 (0.7%)	1 (0.4%)	0 (0.0%)	0 (0.0%)
Supervised education support? (If in mainstream school)	2 (0.8%)	2 (0.7%)	1 (0.4%)	0 (0.0%)	0 (0.0%)
Additional education support? (If in mainstream school)	2 (0.8%)	2 (0.7%)	1 (0.4%)	0 (0.0%)	0 (0.0%)

Table 49 Parenthood data - males and females

Variable	2020	2021	2022	2023	2024
Frequency	60	61	48	25	41
Pregnancy outcome	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neonatal survival	12 (20.0%)	6 (9.8%)	1 (2.1%)	3 (12.0%)	8 (19.5%)
Creatinine prior to conception (umol/L)	8 (13.3%)	1 (1.6%)	0 (0.0%)	2 (8.0%)	1 (2.4%)
Gestational age (best clinical estimate, weeks)	2 (3.3%)	1 (1.6%)	2 (4.2%)	0 (0.0%)	2 (4.9%)
Immunosuppression at conception (Y/N/U)	8 (13.3%)	4 (6.6%)	2 (4.2%)	2 (8.0%)	1 (2.4%)
Congenital condition present?	7 (11.7%)	6 (9.8%)	1 (2.1%)	3 (12.0%)	8 (19.5%)
Foetal gender	8 (13.3%)	8 (13.1%)	0 (0.0%)	3 (12.0%)	8 (19.5%)
Conception type	6 (10.0%)	8 (13.1%)	3 (6.2%)	4 (16.0%)	5 (12.2%)

Table 50 Parenthood birthweight data

Variable	2020	2021	2022	2023	2024
Frequency	53	56	48	22	34
Weight at birth (gms)	8 (15.1%)	5 (8.9%)	5 (10.4%)	3 (13.6%)	6 (17.6%)

Table 51 Parenthood immunosuppression at conception

Variable	2020	2021	2022	2023	2024
Frequency	44	46	41	17	33
CYA Immunosuppression at conception	3 (6.8%)	1 (2.2%)	0 (0.0%)	2 (11.8%)	1 (3.0%)
AZA Immunosuppression at conception	1 (2.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (3.0%)
Pred Immunosuppression at conception	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Tac Immunosuppression at conception	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MMF Immunosuppression at conception	2 (4.5%)	1 (2.2%)	0 (0.0%)	2 (11.8%)	1 (3.0%)
Sirol Immunosuppression at conception	3 (6.8%)	1 (2.2%)	0 (0.0%)	2 (11.8%)	2 (6.1%)
Other Immunosuppression at conception	4 (9.1%)	2 (4.3%)	0 (0.0%)	2 (11.8%)	2 (6.1%)

ANZDATA Missing Data Report



Table 52 Parenthood data - females only

Variable	2020	2021	2022	2023	2024
Frequency	32	34	23	14	21
Diabetes	11 (34.4%)	3 (8.8%)	0 (0.0%)	1 (7.1%)	3 (14.3%)
Hypertension (Somanz 2014 definition)	8 (25.0%)	2 (5.9%)	0 (0.0%)	2 (14.3%)	6 (28.6%)
Pre-Eclampsia	9 (28.1%)	4 (11.8%)	0 (0.0%)	2 (14.3%)	6 (28.6%)
Eclampsia	12 (37.5%)	8 (23.5%)	0 (0.0%)	3 (21.4%)	6 (28.6%)
HELLP Syndrome	12 (37.5%)	8 (23.5%)	0 (0.0%)	3 (21.4%)	6 (28.6%)
Proteinuria ratio	9 (28.1%)	5 (14.7%)	1 (4.3%)	4 (28.6%)	6 (28.6%)
Proteinuria value (last available result pre-pregnancy)	15 (46.9%)	16 (47.1%)	7 (30.4%)	8 (57.1%)	12 (57.1%)
Labour type	7 (21.9%)	5 (14.7%)	1 (4.3%)	2 (14.3%)	6 (28.6%)
Delivery type	7 (21.9%)	5 (14.7%)	0 (0.0%)	1 (7.1%)	6 (28.6%)
Creatinine closest to end of trimester 1 (mmol/L)	13 (40.6%)	13 (38.2%)	2 (8.7%)	7 (50.0%)	8 (38.1%)
Creatinine closest to end of trimester 2 (mmol/L)	16 (50.0%)	15 (44.1%)	2 (8.7%)	7 (50.0%)	10 (47.6%)
Creatinine closest to end of trimester 3 (mmol/L)	19 (59.4%)	15 (44.1%)	2 (8.7%)	8 (57.1%)	11 (52.4%)
Acute rejection during pregnancy	14 (43.8%)	14 (41.2%)	1 (4.3%)	7 (50.0%)	10 (47.6%)
Aspirin drug therapy during pregnancy	8 (25.0%)	6 (17.6%)	0 (0.0%)	1 (7.1%)	4 (19.0%)
EPO drug therapy during pregnancy	8 (25.0%)	5 (14.7%)	0 (0.0%)	3 (21.4%)	4 (19.0%)
Heparin drug therapy during pregnancy	8 (25.0%)	5 (14.7%)	0 (0.0%)	3 (21.4%)	4 (19.0%)
Iron drug therapy during pregnancy	9 (28.1%)	6 (17.6%)	0 (0.0%)	3 (21.4%)	4 (19.0%)
Insulin drug therapy during pregnancy	9 (28.1%)	6 (17.6%)	0 (0.0%)	3 (21.4%)	4 (19.0%)
Metformin drug therapy during pregnancy	9 (28.1%)	6 (17.6%)	0 (0.0%)	3 (21.4%)	4 (19.0%)
Anti-hypertensive drug therapy during pregnancy	8 (25.0%)	6 (17.6%)	0 (0.0%)	2 (14.3%)	4 (19.0%)
Dialysis during pregnancy	9 (28.1%)	6 (17.6%)	0 (0.0%)	2 (14.3%)	6 (28.6%)

Table 53 Parenthood creatinine at delivery

Variable	2020	2021	2022	2023	2024
Frequency	21	23	20	9	16
Creatinine at delivery (umol/L)	3 (14.3%)	4 (17.4%)	0 (0.0%)	2 (22.2%)	4 (25.0%)

Table 54 Parenthood creatinine post delivery

Variable	2020	2021	2022	2023	2024
Frequency	21	23	20	9	11
Creatinine 3 months post delivery (umol/L)	6 (28.6%)	3 (13.0%)	1 (5.0%)	3 (33.3%)	5 (45.5%)

ANZDATA Missing Data Report



Table 55 Non-skin cancer data

Variable	2020	2021	2022	2023	2024
Frequency	845	790	792	817	671
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	18 (2.1%)	16 (2.0%)	10 (1.3%)	1 (0.1%)	10 (1.5%)
Cancer staging code	62 (7.3%)	44 (5.6%)	38 (4.8%)	28 (3.4%)	48 (7.2%)
Type 1st treatment	77 (9.1%)	57 (7.2%)	58 (7.3%)	32 (3.9%)	52 (7.7%)